Literature DB >> 29230398

Insulin Signaling Deficiency Produces Immobility in Caenorhabditis elegans That Models Diminished Motivation States in Man and Responds to Antidepressants.

Julie Dagenhardt1, Angeline Trinh2, Halen Sumner3, Jeffrey Scott3, Eric Aamodt4, Donard S Dwyer1,2.   

Abstract

Defects in insulin signaling have been reported in schizophrenia and major depressive disorder, which also share certain negative symptoms such as avolition, anhedonia, and apathy. These symptoms reflect diminished motivational states, which have been modeled in rodents as increased immobility in the forced swimming test. We have discovered that loss-of-function mutations in the insulin receptor (daf-2) and syntaxin (unc-64) genes in Caenorhabditis elegans, brief food deprivation, and exposure to DMSO produce immobility and avolition in non-dauer adults. The animals remain responsive to external stimuli; however, they fail to forage and will remain in place for >12 days or until they die. Their immobility can be prevented with drugs used to treat depression and schizophrenia and that reduce immobility in the forced swimming test. This includes amitriptyline, amoxapine, clozapine, and olanzapine, but not benzodiazepines and haloperidol. Recovery experiments confirm that immobility is induced and maintained by excessive signaling via serotonergic and muscarinic cholinergic pathways. The immobility response described here represents a potential protophenotype for avolition/anhedonia in man. This work may provide clues about why there is a significant increase in depression in patients with diabetes and suggest new therapeutic pathways for disorders featuring diminished motivation as a prominent symptom.

Entities:  

Keywords:  Antidepressants; Diabetes; Insulin; Major depression; Molecular psychiatry; Motivation; Schizophrenia

Year:  2017        PMID: 29230398      PMCID: PMC5701274          DOI: 10.1159/000478049

Source DB:  PubMed          Journal:  Mol Neuropsychiatry        ISSN: 2296-9179


  64 in total

1.  Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test.

Authors:  D T Chau; P Rada; R A Kosloff; J L Taylor; B G Hoebel
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Akinesia and freezing caused by Na+ leak-current channel (NALCN) deficiency corrected by pharmacological inhibition of K+ channels and gap junctions.

Authors:  Merve Kasap; Kendra Bonnett; Eric J Aamodt; Donard S Dwyer
Journal:  J Comp Neurol       Date:  2016-11-21       Impact factor: 3.215

3.  Neurophysiological differences in reward processing in anhedonics.

Authors:  Gonçalo Padrão; Aida Mallorquí; David Cucurell; Josep Marco-Pallares; Antoni Rodriguez-Fornells
Journal:  Cogn Affect Behav Neurosci       Date:  2013-03       Impact factor: 3.282

Review 4.  Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment.

Authors:  D S Dwyer; R J Bradley; A S Kablinger; A M Freeman
Journal:  Ann Clin Psychiatry       Date:  2001-06       Impact factor: 1.567

5.  Starvation activates MAP kinase through the muscarinic acetylcholine pathway in Caenorhabditis elegans pharynx.

Authors:  Young-jai You; Jeongho Kim; Melanie Cobb; Leon Avery
Journal:  Cell Metab       Date:  2006-04       Impact factor: 27.287

6.  Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia.

Authors:  Ganesan Venkatasubramanian; Seetharamaiah Chittiprol; Narendran Neelakantachar; Magadi N Naveen; Jagadisha Thirthall; Bangalore N Gangadhar; K Taranath Shetty
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

7.  The kinetics of quantal releases during end-plate currents at the frog neuromuscular junction.

Authors:  W Van der Kloot
Journal:  J Physiol       Date:  1988-08       Impact factor: 5.182

Review 8.  Negative symptoms in schizophrenia: avolition and Occam's razor.

Authors:  George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

Review 9.  A framework for studying emotions across species.

Authors:  David J Anderson; Ralph Adolphs
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

10.  Insulin/IGF-1 signaling, including class II/III PI3Ks, β-arrestin and SGK-1, is required in C. elegans to maintain pharyngeal muscle performance during starvation.

Authors:  Donard S Dwyer; Eric J Aamodt
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more
  6 in total

1.  Blockade and reversal of swimming-induced paralysis in C. elegans by the antipsychotic and D2-type dopamine receptor antagonist azaperone.

Authors:  Osama Refai; Randy D Blakely
Journal:  Neurochem Int       Date:  2018-05-22       Impact factor: 3.921

Review 2.  Crossing the Worm-Brain Barrier by Using Caenorhabditis elegans to Explore Fundamentals of Human Psychiatric Illness.

Authors:  Donard S Dwyer
Journal:  Mol Neuropsychiatry       Date:  2018-01-11

3.  Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans.

Authors:  Bárbara Nunes Krum; Airton C Martins; Libânia Queirós; Beatriz Ferrer; Ginger L Milne; Félix Alexandre Antunes Soares; Roselei Fachinetto; Michael Aschner
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

Review 4.  Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1.

Authors:  Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

Review 5.  Catalytic Reaction Model of Suicide.

Authors:  Pamela McPherson; Saveen Sall; Aurianna Santos; Willie Thompson; Donard S Dwyer
Journal:  Front Psychiatry       Date:  2022-03-09       Impact factor: 4.157

6.  Analysis of Major Depression Risk Genes Reveals Evolutionary Conservation, Shared Phenotypes, and Extensive Genetic Interactions.

Authors:  Saveen Sall; Willie Thompson; Aurianna Santos; Donard S Dwyer
Journal:  Front Psychiatry       Date:  2021-07-15       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.